NCT04395950View on ClinicalTrials.gov

Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2020

Primary Completion Date

August 19, 2021

Study Completion Date

August 19, 2021

Conditions
NASH (Nonalcoholic Steatohepatitis)NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
DRUG

PF-05221304

PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)

DRUG

Placebo

Placebo two tablets daily in the morning for 6 weeks

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Columbia University

OTHER

NCT04395950 - Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism | Biotech Hunter | Biotech Hunter